"insurance wont cover them without a successful, peer reviewed, controlled study."
I could be wrong, but I thought there were two successful phase III trials, and at least the latter of the two was published in a peer review journal, Archives of Neurology. A link to the full text of the article is below. I have not had a chance to review it carefully but the claim is that Coprexa is superior to alternatives, which had a greater incidence of neurologic adverse effects.
Treatment of Wilson Disease With Ammonium Tetrathiomolybdate IV. Comparison of Tetrathiomolybdate and Trientine in a Double-blind Study of Treatment of the Neurologic Presentation of Wilson Disease
George J. Brewer, MD; Fred Askari, PhD, MD; Matthew T. Lorincz, PhD, MD; Martha Carlson, PhD, MD; Michael Schilsky, MD; Karen J. Kluin, MS; Peter Hedera, MD; Paolo Moretti, MD; John K. Fink, MD; Roberta Tankanow, MS; Robert B. Dick, MS; Julia Sitterly, BA Arch Neurol. 2006;63:521-527.
ABSTRACT
Objective To compare tetrathiomolybdate and trientine in treating patients with the neurologic presentation of Wilson disease for the frequency of neurologic worsening, adverse effects, and degree of neurologic recovery.
Design A randomized, double-blind, controlled, 2-arm study of 48 patients with the neurologic presentation of Wilson disease. Patients either received 500 mg of trientine hydrochloride 2 times per day or 20 mg of tetrathiomolybdate 3 times per day with meals and 20 mg 3 times per day between meals for 8 weeks. All patients received 50 mg of zinc 2 times per day. Patients were hospitalized for 8 weeks, with neurologic and speech function assessed weekly; discharged taking 50 mg of zinc 3 times per day, and returned annually for follow-up.
Setting A university hospital referral setting.
Patients Primarily newly diagnosed patients with Wilson disease presenting with neurologic symptoms who had not been treated longer than 4 weeks with an anticopper drug.
Intervention Treatment with either trientine plus zinc or tetrathiomolybdate plus zinc.
Main Outcome Measures Neurologic function was assessed by semiquantitative neurologic and speech examinations. Drug adverse events were evaluated by blood cell counts and biochemical measures.
Results Six of 23 patients in the trientine arm and 1 of 25 patients in the tetrathiomolybdate arm underwent neurologic deterioration (P<.05). Three patients receiving tetrathiomolybdate had adverse effects of anemia and/or leukopenia, and 4 had further transaminase elevations. One patient receiving trientine had an adverse effect of anemia. Four patients receiving trientine died during follow-up, 3 having shown initial neurologic deterioration. Neurologic and speech recovery during a 3-year follow-up period were quite good.
Conclusion Tetrathiomolybdate is a better choice than trientine for preserving neurologic function in patients who present with neurologic disease.
Market Data 
Markets 
AI
